Form 4: TriSalus Life Sciences Executive Reports Stock Transactions

Jennifer Stevens, Chief Regulatory Officer of TriSalus Life Sciences, reports acquisition and disposal of common stock on May 19, 2025.

Summary

• On May 19, 2025, Jennifer Stevens, Chief Regulatory Officer of TriSalus Life Sciences, acquired 28,455 shares of common stock at $5.18 per share.
• On the same day, Stevens disposed of 8,704 shares at $5.18 per share to cover tax liabilities associated with the granted Restricted Stock Units (RSUs).
• Following these transactions, Stevens beneficially owns 77,640 shares of TriSalus Life Sciences common stock.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing reflects routine transactions by an officer, with no clear indication of positive or negative outlook.

Positives

• The acquisition of shares by a company officer can be seen as a positive signal.

Negatives

• The sale of shares, even for tax purposes, could be interpreted negatively by some investors.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• Shareholders may be interested in the transactions of company insiders as an indicator of management's confidence.

Key Dates

Keywords

TriSalus Life Sciences, TLSI, Jennifer Stevens, Chief Regulatory Officer, Form 4, Stock Transaction, Beneficial Ownership, RSUs